Wellesley Pharmaceuticals

Treatment for nocturia (excess urination at night afflicts 2 billion) based on safe drugs is ready for phase 2 FDA tests. 4 patents issued.

Newtown, PA, USA
Biotechnology

Company Overview

Our drug cuts nightly bathroom trips 33-100% with 3 synergistic mechanisms of action. Nocturia causes higher death rates, depression, insomnia, lower quality of life & deadly hip fractures. It is perhaps the biggest unmet medical need. Overactive bladder drugs have side effects so 80% stop use within 90 days. We'll conduct a Phase 2a FDA test & then license the patents to a big pharma firm. They'll get FDA approval & launch the product by 2018.

Management Team

  • Default_avatar

    David Alan Dill

    CEO and President
    Unconfirmed
    David is a graduate of Princeton and MIT's Sloan School who spent 19 years in financial jobs at IBM before taking CFO positions at 7 venture backed firms in the last 18 years. He has managed teams from 2 to 350 people, including finance, HR, IT, operations, and legal. He is skilled in team building, outsourcing, mentoring, and negotiating. Recently he left the CFO world to focus on helping those at grave risk due to nocturia.
  • Default_avatar

    Frank Rauscher

    Chief Scientist
    Unconfirmed
    Frank J. Rauscher, III, Ph.D., is Deputy Director for Basic Research at The Wistar Institute. In addition to a doctorate in pharmacology, he has extensive pharmaceutical industry contacts. He is widely recognized for his discoveries in cancer research and has been the Editor-in-Chief for the American Association of Cancer Research flagship journal, Cancer Research. He discovered the science behind Paxerol's 3 synergistic mechanisms of action.
  • Default_avatar

    James Lillard, Jr.

    Scientific Advisor
    Unconfirmed
    Dr. Lillard is a graduate of Ohio State and received his Ph.D. in microbiology & immunology from Kentucky School of Medicine and his MBA from Emory University. He is Associate Dean for Research and Director of the Office of Translational Technologies at Morehouse School of Medicine in Atlanta. Previously, he was a senior scientist at James Graham Brown Cancer Center and was a professor and Vice Chair for Research at University of Louisville.
  • Default_avatar

    Ping Wang

    Patent Attorney
    Unconfirmed
    Dr. Wang earned her medical degree at Kunming Medical College and her law degree at Franklin Pierce law Center. She works at Andrews Kurth LLP, where she concentrates on patent prosecution and patent litigation in the field of pharmaceuticals, among others. She received the Eliot Stellar Award from the Philadelphia Chapter of the Society for Neuroscience and the Lapides Award from the American Urological Society and has published extensively.
  • Default_avatar

    Khurshid Iqbal

    Consultant
    Unconfirmed
    Khurshid Iqbal, Ph.D., is a pharmaceutical R&D executive with 30 years of experience in drug delivery, formulation, and manufacturing. He held senior positions at Hoffman-La Roche, Squibb, and Johnson&Johnson. He is an accomplished scientist with a successful record of IND and NDA filings. His skills and contacts in manufacturing and drug delivery systems are particularly valuable to the company.
  • Default_avatar

    Chike Nathan Okechukwu

    Medical Advisory Board
    Unconfirmed
    Dr. Okechukwu received his medical degree from the University of Nigeria and his Nephrology fellowship at the University of Michigan, Ann Arbor. He is also a Fellow of the American Society of Nephrology, and is a Fellow of the Royal College of Surgeons of Edinburgh, Scotland. Dr. Okechukwu is a board-certified nephrologist and is chairman of the Department of Medicine at Crozer-Chester Medical Center, Upland, PA.
  • Default_avatar

    Ilya Volfson

    Medical Advisory Board
    Unconfirmed
    Dr. Volfson is a graduate of the University of Pennsylvania and Albany Medical College. He joined Associates of Urology of Media, PA later to become Academic Urology of Media, PA in 2006, where he is the president of the largest branch. He is the author of text book chapters on robotic surgery and has also published and presented scientific papers on robotic and laparoscopic surgery at various national and international symposiums.
  • Default_avatar

    Pamela Joy Barton

    Licensing Agent
    Unconfirmed
    Joy is managing partner of Marquant Partners. She was introduced to us with the highest recommendation by a big pharma company. Joy spent 20 years in big pharma (Novartis, Sandoz), biotech (Xenova, Sosei), pharma consulting (Accenture) and academic settings. At pharma firms she managed over $1B in licensing deals and at Marquant has closed consecutive 20 licensing deals. She holds a B.S. in cell biology and a Ph.D. in pharmacology and is a CLP.
  • Default_avatar

    Anthony DelConte

    VP Clinical and Regulatory Affairs
    Unconfirmed
    Dr. DelConte successfully led a leading overactive bladder drug, Enablex, through FDA trials for Novartis. He has also had leading roles at Auxilium and Genaera, as well as a variety of consulting and teaching roles. Dr. DelConte's experience with contract research organizations will be particularly valuable as we finalize plans for the Phase 2a trial.

Company Info

Prototype Ready
6 Employees
Founded: March 2011

Advisors

  • Default_avatar

    Ping Wang

    Lawyer
    Unconfirmed
  • Default_avatar

    Grace Lam

    Accountant
    Unconfirmed

Previous Investors

  • Default_avatar

    David Dill has provided 91% of the funding and Chris Lineberry has provided 9% of the funding.

    Unconfirmed